hotspot -WSS

hotspot

author：fashion 2025-09-06 03:27:53 - browse：6398

UCB website -- health policy coverage from STAT — Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： David Ricks of Eli Lilly: best biopharma CEO of 2023

Wikipedia

WSS

Was Amgen transparent enough on FDA's concern on cancer drug?

Violet CEO on training clinicians to promote more inclusive care

Why health care costs have stayed mostly flat since 2010

Violet CEO on training clinicians to promote more inclusive care

FDA panel signals lack of confidence in Amgen cancer drug data

When women are denied an abortion, their children fare worse than peers

entertainment

hotspot

Sign up for D.C. Diagnosis

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

David Ricks of Eli Lilly: best biopharma CEO of 2023

Cancer drug shortages should be causing more outrage

Liquid biopsy for lung cancer is launched by Delfi

Supreme Court strikes down use of affirmative action

3 questions for the future of Biden's cancer moonshot

Continuity nursing helped my family in our darkest PICU moments

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Bright Health sells Medicare Advantage business to Molina

David Ricks of Eli Lilly: best biopharma CEO of 2023

leisure time

Stroke deaths set to near 10 million globally by 2050

The future of health care in the House

What to expect at HLTH 2023, the health care industry conference

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Phenylephrine and the overlooked value of the placebo effect

Physician executives need more than on

entertainment

entertainment

Wikipedia

knowledge